Last reviewed · How we verify
Jardiance film-coated tablets
Jardiance film-coated tablets is a Small molecule drug developed by Humanis Saglık Anonim Sirketi. It is currently in Phase 1 development.
At a glance
| Generic name | Jardiance film-coated tablets |
|---|---|
| Sponsor | Humanis Saglık Anonim Sirketi |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure (PHASE3)
- Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets (PHASE1)
- A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) (PHASE2)
- Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus
- EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) (PHASE3)
- To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions. (PHASE1)
- Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 12.5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 12.5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany) (PHASE1)
- Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Jardiance film-coated tablets CI brief — competitive landscape report
- Jardiance film-coated tablets updates RSS · CI watch RSS
- Humanis Saglık Anonim Sirketi portfolio CI
Frequently asked questions about Jardiance film-coated tablets
What is Jardiance film-coated tablets?
Jardiance film-coated tablets is a Small molecule drug developed by Humanis Saglık Anonim Sirketi.
Who makes Jardiance film-coated tablets?
Jardiance film-coated tablets is developed by Humanis Saglık Anonim Sirketi (see full Humanis Saglık Anonim Sirketi pipeline at /company/humanis-sagl-k-anonim-sirketi).
What development phase is Jardiance film-coated tablets in?
Jardiance film-coated tablets is in Phase 1.